

## [Paracetamol \(acetaminophen\)](#)

Statut de médicament essentiel

Section:

[2. Medicines for pain and palliative care 2.1. Non-opioids and non-steroidal anti-inflammatory medicines \(NSAIMs\)](#)

Codes ATC: [N02BE01](#)

EMLc

Indication

Pain Code ICD11: [ML0Z](#)

INN

Paracetamol

Type de médicament

Chemical agent

Type de liste

Liste de base

Additional notes

\*Not recommended for anti-inflammatory use due to lack of proven benefit to that effect. \*\*The presence of both 120 mg/5 mL and 125 mg/5 mL oral liquid strengths on the same market would cause confusion in prescribing and dispensing and should be avoided.

Formulations

**Oral > Liquid:** 125 mg per 5 mL ; 120 mg per 5 mL ; 250 mg per 5 mL (EMLc)

**Local > Rectal > Suppository:** 100 mg ; 250 mg (EMLc)

**Oral > Solid > dispersible tablet:** 100 mg (EMLc) ; 250 mg (EMLc)

**Oral > Solid > tablet:** 250 mg ; 325 mg ; 500 mg

Historique des statuts LME

Ajouté pour la première fois en 1977 ([TRS 615](#))

Modifié en 1979 ([TRS 641](#))

Modifié en 1987 ([TRS 770](#))

Modifié en 2007 ([TRS 950](#))

Modifié en 2017 ([TRS 1006](#))

Modifié en 2023 ([TRS 1049](#))

Sexe

Tous

Âge

Aussi recommandé pour les enfants

Équivalence thérapeutique

La recommandation concerne ce médicament spécifique

Renseignements sur le brevet

Patents have expired in most jurisdictions

Lire la suite [sur les brevets](#).

Wikipédia

[Paracetamol \(acetaminophen\)](#)

DrugBank

[Paracetamol \(Acetaminophen\)](#)

Résumé des preuves et recommandation du comité d'experts

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the deletion of the 100 mg tablet formulation from the EML and EMLc - strengths of paracetamol tablets should be specified rather than given in a range - the addition of a 250 mg strength suppository formulation to the EMLc - the addition of paracetamol dispersible tablets (100 mg and 250 mg) to the EMLc - the addition of 250 mg/5mL strength oral liquid formulation to the EMLc - the addition of a note stating "the presence of both 120 mg/5 mL and 125mg/5mL oral liquid strengths on the same market would cause confusion in prescribing and dispensing and should be avoided"